Where next for the Danish adventure?
Investments in the pharmaceutical and biotechnology sectors have traditionally dominated the Danish venture market, until last year when investments dropped by nearly 50%. The sectors are both capital- and knowledge intensive. How will these fare in the current environment?
While the DVCA calls for a growth package to the venture industry, the biotech and pharma start-ups trim their organsiations to prepare for a tough year ahead. Read more in our Denmark focus, pages 16-19.
More on Industry
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
EU FSR could impact PE fundraising with potential rise in ‘clean funds’
FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Redalpine expands leadership team amid CHF 1bn-plus fundraise
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater